医学文献 >>
  • 检索发现
  • 增强检索
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
默认
×
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

Lymphotoxin beta-activated LTBR/NIK/RELB axis drives proliferation in cholangiocarcinoma.

广告
第一作者: Kaiyu,Xu
第一单位: Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg University Hospital, Heidelberg, Germany.;Liver Cancer Center Heidelberg, Heidelberg University Hospital, Heidelberg, Germany.;Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.
作者单位: Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg University Hospital, Heidelberg, Germany.;Liver Cancer Center Heidelberg, Heidelberg University Hospital, Heidelberg, Germany.;Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany. [1] Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg University Hospital, Heidelberg, Germany.;Liver Cancer Center Heidelberg, Heidelberg University Hospital, Heidelberg, Germany.;Department of Medicine A, Hematology, Oncology, Hemostaseology and Pneumology, University Hospital Münster, Münster, Germany. [2] Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.;Computational Oncology, Molecular Diagnostics Program, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany. [3] Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg University Hospital, Heidelberg, Germany.;Liver Cancer Center Heidelberg, Heidelberg University Hospital, Heidelberg, Germany.;Department of RadioOncology and Radiation Therapy, Heidelberg University Hospital, Heidelberg, Germany. [4] Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg University Hospital, Heidelberg, Germany.;Liver Cancer Center Heidelberg, Heidelberg University Hospital, Heidelberg, Germany. [5] Division of Chronic Inflammation and Cancer, German Cancer Research Center Heidelberg (DKFZ), Heidelberg, Germany.;Madrid Institute for Advanced Study (MIAS), Madrid, Spain. [6] Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg University Hospital, Heidelberg, Germany.;Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, Germany. [7] Interfaculty Biomedical Research Facility, University of Heidelberg, Heidelberg, Germany. [8] Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.;Cancer Progression and Metastasis Group, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany.;Faculty of Biosciences, Heidelberg University, Heidelberg, Germany. [9] Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.;Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.;Cancer Progression and Metastasis Group, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany. [10] German Cancer Consortium (DKTK), Heidelberg, Germany.;Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany. [11] Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg University Hospital, Heidelberg, Germany.;German Cancer Consortium (DKTK), Heidelberg, Germany.;Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.;Institute for Pathology, Medical Faculty, Ludwig-Maximilians-University, Munich, Germany. [12] Division of Chronic Inflammation and Cancer, German Cancer Research Center Heidelberg (DKFZ), Heidelberg, Germany. [13] Clinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center, Heidelberg, Germany. [14] Liver Cancer Center Heidelberg, Heidelberg University Hospital, Heidelberg, Germany.;Medical Faculty, Institute for Pathology, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany. [15] Computational Oncology, Molecular Diagnostics Program, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany. [16] German Cancer Consortium (DKTK), Heidelberg, Germany.;Division of Translational Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.;National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany.;Institute of Human Genetics, Heidelberg University, Heidelberg, Germany. [17] Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.;Cancer Progression and Metastasis Group, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany. [18] Division of Chronic Inflammation and Cancer, German Cancer Research Center Heidelberg (DKFZ), Heidelberg, Germany.;The M3 Research Center, Medical Faculty, University Clinic Tübingen (UKT), Tübingen, Germany. [19] Liver Cancer Center Heidelberg, Heidelberg University Hospital, Heidelberg, Germany.;Department of Gastroenterology, Infectious Diseases and Intoxication, Heidelberg University Hospital, Heidelberg, Germany.;Research Group Experimental Hepatology, Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany. [20] Institute of Pathology, RKH Klinikum Ludwigsburg, Ludwigsburg, Germany.;Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland. [21] Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg University Hospital, Heidelberg, Germany.;Liver Cancer Center Heidelberg, Heidelberg University Hospital, Heidelberg, Germany.;German Cancer Consortium (DKTK), Heidelberg, Germany. [22]
DOI 10.1111/liv.16069
PMID 39164890
发布时间 2026-04-15
提交
  • 浏览0
Liver international : official journal of the International Association for the Study of the Liver

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

法律状态公告日 法律状态 法律状态信息

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new医文AI 翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷